Browsing Category
Pharma Industry News
4738 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
InflaRx prepares for key INF904 Phase 2a topline readout in chronic skin inflammation trials
Find out how InflaRx’s INF904 topline Phase 2a data could redefine treatment for hidradenitis suppurativa and chronic spontaneous urticaria.
Darzalex Faspro moves closer to FDA approval as first therapy for high-risk smoldering multiple myeloma
Find out how Darzalex Faspro could become the first FDA-approved therapy for high-risk smoldering multiple myeloma, reshaping early myeloma care.
Rhythm Pharmaceuticals’ IMCIVREE hits regulatory speed bump as FDA extends decision timeline into 2026
Find out how Rhythm Pharmaceuticals’ IMCIVREE FDA review delay could shape the rare obesity treatment market in 2026.
MetaVia unveils breakthrough Phase 2a data showing vanoglipel improves liver markers and glucose control in MASH patients
Find out how MetaVia’s vanoglipel improved liver enzymes and glucose control in its Phase 2a MASH trial — see why investors are taking notice today.
Will UroGen Pharma’s reimbursement tailwind in 2026 turn ZUSDURI into a category-defining cancer therapy?
UroGen Pharma sets $1B peak sales goal for ZUSDURI as permanent J-code from 2026 is expected to drive widespread adoption in outpatient urology settings.
Can Mind Medicine’s $242.8m war chest carry MM120 through three Phase III wins in 2026?
Mind Medicine strengthens its balance sheet with $242.8M funding and eyes three pivotal Phase III data readouts for MM120 in 2026. See why this matters.
Why Tandem Diabetes Care’s shift to pharmacy access could fuel its $1bn 2025 target
Tandem Diabetes Care outlines its path to $1 billion in 2025 revenue driven by pharmacy channel expansion, higher recurring revenue and gross margin improvement.
Sai Life Sciences (NSE: SAILIFE) Q2 FY26 profit doubles on CRDMO demand, high-value tech expansion
Sai Life Sciences profit doubled in Q2 FY26, driven by peptide, ADC, and oligo expansion. See how the CRDMO firm is gaining margin and investor traction.
FDA gives CAPLYTA the go-ahead for major depressive disorder, boosting hopes for better remission rates
Find out how CAPLYTA’s FDA approval for major depressive disorder could redefine depression treatment and improve remission outcomes.
Why Nordic Capital and Permira’s DKK19bn offer for Bavarian Nordic failed despite board approval
Despite a premium offer and board backing, the Nordic Capital–Permira bid for Bavarian Nordic fell short. Explore why the takeover failed and what lies ahead.